Search

everythinglearnresearchcommunity

for

Search:↓

A 17-year-old experienced significant hair loss after switching from topical to oral minoxidil and adding finasteride. The recommendation is to return to topical minoxidil and continue with finasteride or consider dutasteride.

The user updated on their all-natural hair loss protocol, which includes massages, LLLT, Ashwagandha, Supergreens mix, Vitamin D, Castor Oil + DMSO, a specific diet, and headstands. They reported some hair regrowth and improved hair quality, with plans to continue the regimen and monitor results.

The user started losing hair at 20 and began using minoxidil. After seeing further hair loss, they switched to finasteride, causing more hair shedding. They are now using minoxidil, finasteride (topical and oral), microneedling, and ketoconazole shampoo for recovery.

The potential of using a specific antibody, HMI-115, as a treatment for hair loss alongside traditional treatments such as minoxidil and finasteride. The user suggests trying either a 240 mg or 30 mg dose to see if it works.

The user has been using liposomal topical finasteride since late 2022, progressively increasing the dose, but DHT serum levels remain largely unchanged. Despite using finasteride, minoxidil, microneedling, and ketoconazole, hair condition has neither improved nor worsened.

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

Hair loss itch is caused by DHT attacking follicles and stimulating nerves. Finasteride users who respond well don't experience this itch.

The user experienced significant hair loss due to health issues and has only taken vitamins for recovery. They are seeking advice on regrowth progress after two months.

The conversation discusses the effectiveness of RU58841 for hair loss compared to pyrilutamide, which failed to show significant hair regrowth in trials. Some users report personal side effects with RU58841 and question the criteria for success in hair loss treatments.

The user has been using pyrilutamide, topical finasteride, and 15% minoxidil for hair growth for almost 4 years. Despite mixed responses from others, the user reports seeing progress, especially with the addition of pyrilutamide, and plans to continue the regimen.

Pyrilutamide's effect on sebum production and scalp inflammation is unclear, with users noting no significant changes. Isotretinoin is mentioned as effective for reducing sebum, while Dutasteride and various shampoos have limited impact on oiliness and seborrheic dermatitis.

Low-level laser therapy (LLLT) devices may help thicken existing hair but are not effective for regrowing hair on bald areas. Users suggest sticking with finasteride, minoxidil, and dermapenning, as LLLT devices like Capillus are expensive and results are mixed.

The user has been using dutasteride, lymecycline, betamethasone, and minoxidil for hair loss but struggles with eczema and dry skin. They feel hopeless as no treatments or moisturizers have helped, and they are concerned about their appearance due to their soft facial features.

The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.

The user shared their bloodwork results showing DHT at 17 ng/dl and testosterone at 287 ng/dl, with a slight Vitamin D deficiency. They are seeking opinions on these levels and have an upcoming dermatologist appointment.

The user shared their 5-year hair recovery journey using finasteride, RU58841, dutasteride, minoxidil, and microneedling, noting mixed progress but overall improvement. They regret not starting treatment earlier and recently received positive health feedback from their doctor.

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. Pyrilutamide cleared for phase 3 clinical trial in China.

Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.

A 16 year old's experience with using pyrilutamide to treat hair loss, and the potential side effects of adding tretinoin to minoxidil and finasteride treatments.

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.

An 18-year-old male with hair loss is considering starting finasteride but is concerned about potential side effects like gynecomastia due to his prolactin levels. He seeks guidance on whether his bloodwork indicates it's safe to begin treatment.

The conversation is about adding a low dose of pyrilutamide to a hair loss treatment regimen. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses concerns about the effectiveness of finasteride for hair loss. The user is worried about being a non-responder to the treatment.

A user visited a dermatologist for hair loss concerns and was prescribed a hair lotion called "Lotion revolotion evdermia," which is meant for hair toning, hydration, and anti-aging, not regrowth. The user found the dermatologist's behavior and the prescription to be questionable.

The user experienced noticeable hair regrowth after using finasteride for 2 years, oral minoxidil for 1 year, and recently starting dermarolling. The right temple shows significant improvement, while the left remains similar.

The user's hair appears to have improved, looking thicker and healthier, especially around the temples, after using topical minoxidil, finasteride, dutasteride, and tretinoin. Most participants agree the last picture shows significant improvement, though one disagrees.

The potential release date for results from a phase 2 trial of Pyrilutamide, a hair loss treatment that combines Minoxidil, Finasteride and RU58841. It was agreed that the results are expected to be released in June 2022.

The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.

Pyrilutamide's 0.5% solution showed minimal improvement, while the 1% solution appears more promising but costly. The user is currently using finasteride and oral minoxidil and considering adding Pyrilutamide if effective and affordable.

Pyrilutamide's mainstream product release date is discussed. Side effects found in studies are also questioned.